MEDICINES TRANSPARENCY ALLIANCE PHILIPPINES ON THE PATH TO MEDICINES FOR ALL
|
|
- Meghan Riley
- 5 years ago
- Views:
Transcription
1 MEDICINES TRANSPARENCY ALLIANCE PHILIPPINES ON THE PATH TO MEDICINES FOR ALL
2 Our challenges Improving access to quality medicines for the most vulnerable in the Philippines is an enormous challenge. More than a quarter of the Philippine population was still in poverty when MeTA began, 1 making affordability of medicines critical. Yet statistics showed that most of the nation s health spending was being borne by households. Of household expenditure on health, two-thirds was spent on medicines. The reasons Philippines patients have been responsible for such a significant proportion of out-of-pocket medicines costs are many, but one of the key challenges has been inefficiencies in medicines procurement. Prices paid for medicines have varied from one hospital to another sometimes even within hospitals. Regulation of the medicines supply chain has been weak and storage practices have been wanting. Patients have been left out of the healthcare dialogue, and there has been a lack of awareness among consumers about what health benefits they are entitled to. The situation demands a comprehensive package of policy responses to pave the way to improved access to quality medicines. 1 Philippines National Demographic and Health Survey Manila: National Statistics Office; 2009 ( accessed 6 July 2015).
3 PHILIPPINES Our response The Medicines Transparency Alliance (MeTA) pilot began in the Philippines in Its mission was to contribute to good governance, transparency and accountability across the medicines supply chain, by engaging all stakeholders with an interest in improving health outcomes. Since then, a small secretariat overseen by a board of trustees has built MeTA into an 80-member alliance of individuals and organizations from civil society, government and industry. MeTA has brought academics, civil society organizations and patients around the same table as professional associations, the private sector and government in meaningful dialogue. Issues are identified and debated. Points of contention often remain, but so too is consensus reached. The process has elevated the concerns of the patient in the policy-making process and has brought new scrutiny to government decision making. MeTA has laid the foundations for increasingly accessible safe, effective and quality medicines and their rational use. The Philippines is one of seven countries to adopt MeTA the programme is also active in Ghana, Jordan, Kyrgyzstan, Peru, Uganda and Zambia. It is currently funded by the UK Government through the Department for International Development. Our achievements Our policy dialogue series helped raise stakeholder awareness of priority health issues, and provided the platform for consultation and collaborative action. We built consensus on the need for ethical medicines promotion, encouraging the local pharmaceutical industry to finalize its own code of ethics. We drew attention to the need to engage and empower patient organizations and civil society, prompting the Department of Health to commit to engage the sectors in policy formulation, programme planning and implementation and monitoring. We trained educators and healthcare professionals on issues including ethical promotions and good pharmacy practice standards. We supported civil society organizations to design citizen-monitoring tools that will be used to determine grassroots awareness and the availability of medicine access programmes and patient benefit packages. 1
4 Medicines Transparency Alliance Our journey Forming an alliance to strengthen policy The launch of the MeTA pilot coincided with a major development in medicines policy in the Philippines: the passage of the Universally Accessible Cheaper and Quality Medicines Act of Among the law s main objectives are to allow early registration of medicines prior to patent expiry, prevent registration of medicines for new uses and cap prices of key medicines. While the pharmaceutical industry was deeply involved in the debate over the law, civil society and elderly groups campaigned from the sidelines. Patients weren t missing in the sense that they didn t exist, but because their voice wasn t loud enough, says MeTA s Chairman, the former Governor of Bulacan, one of the Philippines largest provinces, Roberto Pagdanganan. Their voice wasn t articulate enough and, therefore, not heard enough. MeTA changed that. For the first time it has given patient groups, as well as academics, a seat at the table alongside government, professional associations and industry. Civil society now has a platform where we can float and share so many things, says the chief executive officer of the National Pharmaceutical Foundation CSO, Teofila Remotigue. We can do position papers for trade agreements, for example. MeTA is very helpful in making sure that there is monitoring and following up on policy and I think the Department of Health (DOH) is listening to us because it is opening the door. MeTA has made medicines policy making more efficient and robust. The chief of the DOH s Pharmaceutical Division, Dr Melissa Guerrero, says MeTA has elevated patients concerns in the policy-making process. Before, patients had been nowhere when we crafted the policies, she says. We had long wanted to engage them in all our policies, because, after all, the policies should benefit the patients. 2
5 PHILIPPINES Key to how MeTA has worked Robust evidence gathered and analysed Dissemination of evidence and multi-stakeholder dialogue Policy or practice recommendations Action Advocacy and awareness raising MeTA s contribution to increasing transparency in the pharmaceutical supply chain Pharmaceutical Sector Scan; Data Disclosure Survey; Facility and Household Survey; Survey of government procurement prices for essential medicines; Mapping of medicine entitlement programmes of the national government. Round-table discussions (MeTA discussion series) where results of studies and surveys are disseminated to all relevant stakeholders. Training workshops for civil society (CHAT discussion series) on priority issues such as bilateral trade agreements, intellectual property rights and public health, theory of change, and social accountability mechanisms. Publication of all MeTA studies and reports in the websites of DOH and other stakeholder groups. Regular consultations with the DOH on specific issues related to universal health care, medicine access programmes and pharmaceutical supply. Policy recommendations from annual MeTA forums considered as key inputs in the implementation of the universal health care programme, and in the institution of reforms in the pharmaceutical sector. Stakeholder engagement in the DOH Advisory Council on the implementation of the Cheaper and Quality Medicines Act. Reforms and actions taken to improve and streamline DOH medicine access programmes to address duplication and overlaps, distribution inefficiencies, lack of public awareness, and weak monitoring. Development of social accountability/citizen monitoring tools (Medicines Watch and Philhealth Watch) to empower civil society to monitor and provide feedback on government medicines access and health insurance benefits programmes. Advocacy for the implementation of specific initiatives provided for in the Cheaper Medicines Act and in the law strengthening the Food and Drug Administration. 3
6 Medicines Transparency Alliance Improving access to safe and quality medicines MeTA s value as a venue for monitoring policy was highlighted after the DOH developed a drug price reference index to be used to cap medicine prices. While monitoring the implementation of the cap, MeTA stakeholders became concerned that only the price of expensive branded medicines had fallen, mainly to the benefit of those wealthy enough to afford them. It was agreed that to improve access to medicines for lowincome earners, more comprehensive implementation of the complex Philippines benefits packages system, called Philhealth, was needed. In 2013, MeTA commissioned the first independent mapping of medicines access programmes to highlight gaps. It disseminated the findings among stakeholders, including MeTA s CSO partner, the Coalition for Health Advocacy and Transparency (CHAT), at a MeTA round-table discussion. The study prompted MeTA and CHAT to develop community monitoring tools that will enable citizens to report on the availability, price and quality of medicines and Philhealth benefits packages. Concern for inefficiencies in the medicines management cycle at the level of local governments prompted MeTA to collaborate with the DOH on the rollout of pharmaceutical supply chain management training targeting local government health facilities. Its goal is to institutionalize a system that is aligned with global standards as well as with the national system. MeTA, in collaboration with its partners, also delivered training on substandard and counterfeit medicines, to raise awareness about their dangers. MeTA is also among the members of the Coalition for Safe Medicines advocacy group that was convened by the Food and Drug Administration (FDA). MeTA s contribution to improving governance Survey /needs analysis of the drug supply chain processes in local governments; Stakeholder mapping and development of the framework for the engagement and empowerment of patient organizations in the Philippines; Study on the framework for the institutionalization of patient engagement and consultation within the DOH structure. Pilot course on leadership, governance and transparency in pharmaceutical management for local government units. Training workshop on pharmaceutical supply chain management for local government health facilities. Participation in the Good Governance in Medicines (GGM) program, in collaboration with the WHO and DOH, specifically in the grant of awards for best practices in GGM among health facilities. Regional training workshops on the Philippine Practice Standards for Pharmacists and the joint WHO/FIP Guidelines on Good Pharmacy Practice. TA studies and reports in the websites of DOH and other stakeholder groups. DOH initiatives to streamline and rationalize internal medicines supply chain management system to address current gaps and overlaps. Initiatives to align national and local government medicines supply chain systems to improve overall access to essential medicines. Agreement to roll out capacity-building workshops on pharmaceutical supply chain management to all local governments. DOH and FDA commitment to engage and consult patient organizations and civil society organizations in policy making, and program planning, implementation and monitoring. 4
7 PHILIPPINES The push for ethical standards Medicines promotion is weakly regulated in the Philippines, but MeTA sparked a push for change by commissioning an influential study into the issue in It opened the eyes of the government to the fact that there really needs to be standards, because they affect how physicians practice medicine and patient care, the DOH s Dr Guerrero says. It s not just the price of the medicines that is affected when pharmaceutical companies promote to doctors, it is also the quality of care it leads to doctors prescribing unnecessarily. Many stakeholders were calling for a code of ethics, but the local industry was concerned that the push was being driven by multinational research companies. MeTA Philippines vice-chairman and senior official in the Philippines largest pharmaceutical company, United Laboratories, Jose Maria Ochave, says it became clear via MeTA that a code had broad support. MeTA became the forum for looking at ethical marketing practices because of the links that MeTA provided. The domestic and the multinational pharmaceutical sectors talked to each other normally they wouldn t. They agreed to take a common stand on restrictions on marketing. MeTA has sought to buttress the push for ethical guidelines by strengthening civil society s involvement, with the establishment of the ETHIKOS Movement a broach CSO coalition to campaign for ethics in medicines promotion. MeTA piloted training modules on pharmaceutical promotion, and sought to integrate these in the regular curriculum of pharmacy and medicine schools. MeTA s contribution to improving the safety, efficacy and quality of medicines Study on barriers to reporting suspected substandard/spurious/falsely-labelled/ falsified/counterfeit (SSFFC) Medical Products. MeTA Discussion Series: A Multi-stakeholder Approach to Strengthening Community Advocacy for Safe and Quality Medicines a discussion on the dangers and risks of SSFFC and possible mechanisms to address the challenge. MeTA presentation during the celebration of the National Consciousness Week Against Counterfeit Medicines to support the WHO SSFFC initiative. Emphasis on training courses on the dangers and risks of counterfeit medicines, and how to address them, in school curricula, and as a continuing professional development course for licensed health and allied health professionals. Patient and civil society-led monitoring and reporting of suspected SSFFC medical products. Advocacy and information campaign on the dangers and risks of SSFFC medical products targeting patients and consumers. Participation in the Coalition for Safe Medicines, an advocacy and information group convened by the FDA. 5
8 Medicines Transparency Alliance A new force in medicines policy Many of those who pushed for the passage of the Cheaper Medicines law and advocated for reforms are now active members of MeTA, and see themselves as a custodian of the law with a responsibility to protect, monitor and evaluate it. Some see that role becoming increasingly important in the face of new challenges. Pharmaceutical sector stakeholders now consider MeTA an arm of medicines policy making. MeTA vicechairman Jose Maria Ochave says there is enormous value in an alliance of different interests supporting the government to see through commitments, such as the national government s pledge to have universal health care in the Philippines. The value of MeTA is really communication if you want consensus you have to be a willing participant in transparent dialogue in a multi-stakeholder platform and that is the value of MeTA. MeTA has many plans for the future, including improving the oversight of pharmaceutical promotion; institutionalizing patient engagement and consultation in DOH planning and policy; addressing barriers to reporting substandard and counterfeit medicines and improving supply chain management capacities among local governments. 6
9 PHILIPPINES What we ve learned Building trust and cooperation between civil society, the private sector and government leads to strong and efficient policy making. Information sharing and disclosure are encouraged and gaps in knowledge are best addressed when everyone is around the same table engaged in healthy dialogue. The multi-stakeholder approach improves transparency. When information is shared and disclosed among all stakeholders, there are improved opportunities for evidence-based decision making. Stakeholders are then better able to demand accountability from the government for the use of resources and attainment of health targets. Sustainable change is possible when all stakeholders are engaged in the entire process of policy making, and in the planning, execution and monitoring of health programmes. 7
10 Medicines Transparency Alliance MeTA Philippines members 8 Government Department of Health: Dr Anna Melissa S. Guerrero, Chief, Pharmaceutical Division Food and Drug Administration: Maria Lourdes C. Santiago, Deputy Director General Philippine Health Insurance Corporation (Philhealth): Dr Francisco Z. Soria, Jr, Vice President, Quality Assurance Group PITC Pharma, Inc.: Jose A. Capistrano, Jr, President Pharmaceutical Industry Drugstores Association of the Philippines: Celia Carlos, Past Chairman of the Board PHAPCares Foundation: Dr Dr Edgar L. Posadas, Managing Director Pharmaceutical and Healthcare Association of the Philippines: Teodoro B. Padilla, Executive Director Philippine Chamber of the Pharmaceutical Industry: Tomas Marcelo Luke G. Agana III, Past President GSK Philippines: Atty. Mailyn M. Ocampo, Director Novartis Philippines: Christine Fajardo, Director The Generics Pharmacy: Benjamin Liuson, President Health Professional Associations Asia Pacific Institute of Medicines Management: Leonila Ocampo, President Manila Pharmacists Society: Reynaldo Maxlito Umali, President Philippine Medical Association: Dr Minerva P. Calimag, President Philippine Pharmacists Association: Dr Olivia M. Limuaco, President Philippine Society of Hospital Pharmacists: Hazel Faye Docuyanan, President Private Hospitals Association of the Philippines: Dr Rustico A. Jimenez, President Young Pharmacists Group: Bryan Posadas, President Patient Organizations Philippine Alliance of Patients with Chronic Illness/ Psoriasis Philippines: Josefino de Guzman, President Philippine Alliance of Patient Organizations: Maria Fatima G. Lorenzo, President Civil Society Alt*Health Foundation: Dr Elenita Loida A. Pedrosa, Executive Director Alternative Budget Initiative Health Cluster: Mercedes Fabros, Lead Ayos na Gamot sa Abot-kayang Presyo Coalition: Atty. Paula Mae B. Tanquieng Center for Empowerment and Development of the Elderly and Seniors: Salvacion Basiano, President Civika Institute: Dr Elmer Soriano, President Damayan ng Maralitang Pilipinong Api: Emma Manjares, Executive Director HealthJustice Philippines: Ralph Emerson Degollacion, Project Coordinator Medical Action Group: Edeliza Hernandez, Executive Director Minimal Government Thinkers: Bienvenido Oplas, Jr, President National Pharmaceutical Foundation: Teofila Remotigue, Chief Executive Officer Task Force Kilos Damit: Laudicia Casana, President Womanhealth Philippines: Ana Maria R. Nemenzo, National Coordinator Academe University of the Philippines College of Medicine: Dr Francisco Tranquilino, College Secretary and Special Assistant to the Dean University of the Philippines Department of Pharmacology: Dr Noel Juban University of the Philippines College of Pharmacy: Dr Imelda Pena, Dean University of the Philippines Universal Health Care Study Group: Dr Ramon Pedro Paterno, Dr Cecilia S. Acuin University of Makati: Ma. Faye Nenette Cariaga, Donna Felix University of the Philippines School of Economics: Lourdes Desiree Cembrano, Consultant Projects Tulay sa Kalusugan (Improving Access to Medicines Project in the Philippines): Dr Anthony G. Faraon, Project Lead Health Sector Catalyst/LUNAS: Dr Bryan Albert Lim Individuals Roberto M Pagdanganan Atty. Jose Maria A. Ochave Cecilia C. Sison Normita D. Leyesa Reiner W. Gloor Dr Arthur T. Catli International Partners World Health Organization Western Pacific Regional Office: Dr Klara Tisocki, Lead, Essential Medicines and Health Technologies Office of the WHO Representative in the Philippines. Dr Julie Lyn Hall, WHO Representative/Roderick L. Salenga, National Professional Officer Essential Medicines and Health Technologies EU Delegation to the Philippines. Diana van Daele The World Bank. Dr Roberto Rosadia, Health Specialist
11 WHO/EMP/PAU/ World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO web site ( or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: ; fax: ; Requests for permission to reproduce or translate WHO publications whether for sale or for non-commercial distribution should be addressed to WHO Press through the WHO website ( The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Photos: WHO/Mark Lester Romulo Sotelo/Christine Aileen Ching. Design and layout: L IV Com Sàrl, Villars-sous-Yens, Switzerland. Printed by the WHO Document Production Services, Geneva, Switzerland.
12 PHILIPPINES MEDICINES TRANSPARENCY ALLIANCE The Medicines Transparency Alliance (MeTA) initiative is grounded in the theory that shining a light on an often opaque system will illuminate problems, improve efficiencies and empower stakeholders to hold decision makers accountable. The hypothesis is that making information transparent and bringing stakeholders together to discuss it will improve access to quality medicines for those who need them. The global initiative began as a pilot in 2008 in seven countries, with the aim of establishing the multi-stakeholder platforms and collecting baseline data. The current phase, Phase 2, has focussed on making information transparent and using evidence to make policy recommendations. This document is one in a series of brochures that has been produced to share the highlights from the first three years of the second phase of the MeTA programme in each of the seven countries. The project has been funded by the UK Department for International Development. WHO, in collaboration with Health Action International, has managed the global programme and provided in-country support. As Phase 2 comes to an end in 2015, countries are considering options for long-term programme sustainability. To contribute, to get involved or for more information, contact: Julie Hall WHO Country Office Philippines Klara Tisocki WHO Regional Office for the Western Pacific Philippines Gilles Forte WHO Essential Medicines and Health Products Department Switzerland hallju@who.int tisockik@wpro.who.int forteg@who.int
ENRICHING THE POLICY-MAKING PROCESS THROUGH MULTISTAKEHOLDER DIALOGUE
ENRICHING THE POLICY-MAKING PROCESS THROUGH MULTISTAKEHOLDER DIALOGUE WHO BI-REGIONAL CONSULTATION ON GOOD GOVERNANCE FOR IMPROVED ACCESS TO MEDICINES 9 Nov 2015 Manila Philippines 1 INTRODUCTION MeTA:
More informationEU/ACP/WHO RENEWED PARTNERSHIP
EU/ACP/WHO RENEWED PARTNERSHIP Strengthening pharmaceutical systems and improving access to quality medicines ETHIOPIA 2012 2016 ABOUT THE RENEWED PARTNERSHIP IN ETHIOPIA The Ethiopian segment of the Renewed
More informationWHO Library Cataloguing in Publication Data Health service planning and policy-making : a toolkit for nurses and midwives.
i WHO Library Cataloguing in Publication Data Health service planning and policy-making : a toolkit for nurses and midwives. 1. Delivery of health services -- organization & administration. 2. Policy making.
More informationGood Governance for Medicines Medicines as part of Universal Health Coverage
Good Governance for Medicines Medicines as part of Universal Health Coverage Gilles Forte World Health Organization Department of Essential Medicines and Health Products Geneva 1 Substantial budgets are
More informationImproving Patient Safety: First Steps
The African Partnerships for Patient Safety Framework Improving Patient Safety: First Steps This resource outlines an approach to improving patient safety using a partnership model, structured around 12
More informationRegional consultation on the availability and safety of blood transfusion during humanitarian emergencies
Summary report on the Regional consultation on the availability and safety of blood transfusion during humanitarian emergencies WHO-EM/LAB/387/E Tunis, Tunisia 15 16 May 2016 Summary report on the Regional
More informationGuidelines for Preventive and Social Medicine/Community Medicine/Community Health Curriculum in the Undergraduate Medical Education
SEA-HSD-325 Distribution: General Guidelines for Preventive and Social Medicine/Community Medicine/Community Health Curriculum in the Undergraduate Medical Education World Health Organization 2010 All
More informationStrengthening nursing and midwifery in the Eastern Mediterranean Region
WHO-EM/NUR/429/E Strengthening nursing and midwifery in the Eastern Mediterranean Region A framework for action 2016-2025 Strengthening nursing and midwifery in the Eastern Mediterranean Region A framework
More informationInformal note on the draft outline of the report of WHO on progress achieved in realizing the commitments made in the UN Political Declaration on NCDs
Informal note on the draft outline of the report of WHO on progress achieved in realizing the commitments made in the UN Political Declaration on NCDs (NOT AN OFFICIAL DOCUMENT OR FORMAL RECORD 1 ) Geneva,
More informationRegional meeting of directors of national blood transfusion services
Summary report on the Regional meeting of directors of national blood transfusion services WHO-EM/LAB/386/E Tunis, Tunisia 17 19 May 2016 Summary report on the Regional meeting of directors of national
More informationAnalysis in the light of the Health 2020 strategy By Roberto Bertollini, Celine Brassart and Chrysoula Galanaki
Review of the commitments of WHO European Member States and the WHO Regional Office for Europe between 1990 and 2010 Analysis in the light of the Health 2020 strategy By Roberto Bertollini, Celine Brassart
More informationSpread Pack Prototype Version 1
African Partnerships for Patient Safety Spread Pack Prototype Version 1 November 2011 Improvement Series The APPS Spread Pack is designed to assist partnership hospitals to stimulate patient safety improvements
More informationHEALTH SYSTEMS IN TRANSITION THE PHILIPPINES HEALTH SYSTEM REVIEW 2011 PHILIPPINE LIVING HITS 2013,2014
HEALTH SYSTEMS IN TRANSITION THE PHILIPPINES HEALTH SYSTEM REVIEW 2011 PHILIPPINE LIVING HITS 2013,2014 Leizel P Lagrada MD MPH PhD Global Forum on Research and Innovation for Health 2015/ PICC Philippine
More informationIn 2015, WHO intensified its support to Member
Strengthening health systems for universal health coverage Universal health coverage In 2015, WHO intensified its support to Member States in order to accelerate progress towards universal health coverage,
More information4 October 2012, Bad Gastein, Austria Report of the meeting
Strengthening the response to noncommunicable diseases in central Asia and eastern Europe 4 October 2012, Bad Gastein, Austria Report of the meeting Strengthening the response to noncommunicable diseases
More informationPlanning meeting to set up a diploma in mental health, human rights and law at the International Islamic University, Islamabad, Pakistan
Summary report on the Planning meeting to set up a diploma in mental health, human rights and law at the International Islamic University, Islamabad, Pakistan WHO-EM/MNH/208/E Cairo, Egypt 24 26 September
More informationImproving Access to Medicines Project in the Philippines the Palawan Pilot:
Improving Access to Medicines Project in the Philippines the Palawan Pilot: A Public-Private Partnership in Addressing Accessibility, Availability & Affordability Anthony R.G. Faraon, MD, MPH Project Lead
More informationWorking document QAS/ RESTRICTED September 2006
RESTRICTED September 2006 PREQUALIFICATION OF QUALITY CONTROL LABORATORIES Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies The
More informationAfrican Partnerships for Patient Safety. Evaluation Handbook April 2012
African Partnerships for Patient Safety Evaluation Handbook April 2012 WHO/IER/PSP/2012.8 World Health Organization 2012 The designations employed and the presentation of the material in this publication
More informationPhilippine Strategic TB Elimination Plan: Phase 1 (PhilSTEP1)
2017 2022 Philippine Strategic TB Elimination Plan: Phase 1 (PhilSTEP1) 24 th PhilCAT Convention August 16, 2017 Dr. Anna Marie Celina Garfin NTP-DCPB, Department of Health Reasons for developing the NTP
More informationWHO COUNTRY COOPERATION STRATEGY
WHO COUNTRY COOPERATION STRATEGY REGIONAL ANALYSIS Review and recommendations for a better formulation and utilization of Country Cooperation Strategies Western Pacific Region WHO COUNTRY COOPERATION
More informationIn 2012, the Regional Committee passed a
Strengthening health systems for universal health coverage In 2012, the Regional Committee passed a resolution endorsing a proposed roadmap on strengthening health systems as a strategic priority, as well
More informationACHIEVING QUALITY UNIVERSAL HEALTH COVERAGE THROUGH BETTER WATER, SANITATION AND HYGIENE SERVICES IN HEALTH CARE FACILITIES
ACHIEVING QUALITY UNIVERSAL HEALTH COVERAGE THROUGH BETTER WATER, SANITATION AND HYGIENE SERVICES IN HEALTH CARE FACILITIES A focus on Cambodia and Ethiopia ACHIEVING QUALITY UNIVERSAL HEALTH COVERAGE
More informationWHO Library Cataloguing-in-Publication Data
WHO Country Cooperation Strategies Guide 2010 WHO Country Cooperation Strategies Guide 2010 WHO Library Cataloguing-in-Publication Data WHO country cooperation strategies guide 2010. 1. National health
More informationMeeting of the European Parliament Interest Group on Carers
Meeting of the European Parliament Interest Group on Carers Brussels, 20 October 2015 Meeting report Marian Harkin MEP opened the meeting with a special welcome to the visiting Irish carers group. She
More informationIntegrated Pharmacist Services in the Community. Evolving consumer focused pharmacist services
Integrated Pharmacist Services in the Community Evolving consumer focused pharmacist services Acknowledgement The 20 District Health Boards wish to thank everyone who took part in the National and Regional
More informationMedication Without Harm
Medication Without Harm WHO Global Patient Safety Challenge WHO/HIS/SDS/2017.6 World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike
More informationINTERPROFESSIONAL EDUCATION CASE STUDY. Resources. for Health Observer. Human
Human Resources for Health Observer Issue n o 14 INTERPROFESSIONAL EDUCATION CASE STUDY Master of Science degree programme in Reproductive Health at Kamuzu College of Nursing, Malawi WHO Library Cataloguing-in-Publication
More informationPPPs in Health Manila Developing Models, Ensuring Sustainability: Perspectives from Asia and Europe
EVENT BRIEF as of 02 October 2012 Convenors PPPs in Health Manila 2012 1 Developing Models, Ensuring Sustainability: Perspectives from Asia and Europe October 23-25, 2012 Manila, Philippines Auditoriums
More informationHigh Level Pharmaceutical Forum
High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following
More informationRPS Strategy
RPS Strategy 2016-2021 OUR PURPOSE The Royal Pharmaceutical Society (RPS) leads the profession of pharmacy to improve the public s health and wellbeing. WHO WE ARE The RPS is the professional membership
More informationWHO MIDWIFERY EDUCATOR CORE COMPETENCIES: BUILDING CAPACITIES OF MIDWIFERY EDUCATORS
WHO MIDWIFERY EDUCATOR CORE COMPETENCIES: BUILDING CAPACITIES OF MIDWIFERY EDUCATORS WHO Library Cataloguing-in-Publication Data: Midwifery educator core competencies: building capacities of midwifery
More informationUsing lay health workers to improve access to key maternal and newborn health interventions in sexual and reproductive health
Using lay health workers to improve access to key maternal and newborn health interventions in sexual and reproductive health improve access to key maternal and newborn health interventions A lay health
More informationIMCI. information. Integrated Management of Childhood Illness: Global status of implementation. June Overview
WHO/CHS/CAH/98.1B REV.1 1999 ORIGINAL: ENGLISH DISTR.: GENERAL IMCI information INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (IMCI) DEPARTMENT OF CHILD AND ADOLESCENT HEALTH AND DEVELOPMENT (CAH) HEALTH
More informationBRIDGING THEORY AND PRACTICE
BRIDGING THEORY AND PRACTICE The Health Systems Research Management of the Department of Health Philippines Maria Rosario S. Vergeire, MD, MPH Chief Health Research Division Health Policy Development and
More informationInternational Pharmaceutical Federation Fédération internationale pharmaceutique. Standards for Quality of Pharmacy Services
International Pharmaceutical Federation Fédération internationale pharmaceutique PO Box 84200, 2508 AE The Hague, The Netherlands Standards for Quality of Pharmacy Services Standards are an important part
More informationReport from the National Quality Forum: National Priorities Partnership Quarterly Synthesis of Action In Support of the Partnership for Patients
Report from the National Quality Forum: National Priorities Partnership Quarterly Synthesis of Action In Support of the Partnership for Patients August 2012 Supporting Patient Safety through the National
More informationJoint external evaluation of IHR Core Capacities of the Republic of Uganda. Executive summary June 26-30, 2017
Joint external evaluation of IHR Core Capacities of the Republic of Uganda Executive summary June 26-30, 2017 WHO/WHE/CPI/SUM/2017.39 World Health Organization 2017 Some rights reserved. This work is available
More informationHow the contract model becomes the main mode of purchasing: a combination of evidence and luck in Thailand
How the contract model becomes the main mode of purchasing: a combination of evidence and luck in Thailand Viroj Tangcharoensathien, Winai Swasdiworn, Pongpisut Jongudomsuk, Samrit Srithamrongsawat, Walaiporn
More informationShared Vision, Shared Outcomes: Building on the Foundation of Collaboration between Public Health and Comprehensive Primary Health Care in Ontario
Shared Vision, Shared Outcomes: Building on the Foundation of Collaboration between Public Health and Comprehensive Primary Health Care in Ontario Submission from the Association of Ontario Health Centres
More informationPolicy brief. Benchmarking the fairness of health sector reform in the Philippines. Policy brief
WHO/RHR/09.07 Policy brief Policy brief Susan Bender/Photoshare Benchmarking the fairness of health sector reform in the Philippines Introduction The Benchmarks of Fairness framework was conceived in the
More informationInnovation, Information, Evidence and Research INNOVATING AND EMPOWERING PEOPLE FOR HEALTH
Innovation, Information, Evidence and Research INNOVATING AND EMPOWERING PEOPLE FOR HEALTH 2 INTRODUCTION Central to the World Health Organization s (WHO) mandate and reform agenda are activities to expand
More informationLaboratory Assessment Tool
WHO/HSE/GCR/LYO/2012.2 Laboratory Assessment Tool Annex 1: Laboratory Assessment Tool / System Questionnaire April 2012 World Health Organization 2012 All rights reserved. The designations employed and
More informationGuide to Implementation. A Guide to the Implementation of the WHO Multimodal Hand Hygiene Improvement Strategy
Guide to Implementation A Guide to the Implementation of the WHO Multimodal Hand Hygiene Improvement Strategy GUIDE TO IMPLEMENTATION CONTENTS DEFINITION OF TERMS 4 KEY TO SYMBOLS 5 PART I I.1. OVERVIEW
More informationA Roadmap for SDG Implementation in Trinidad and Tobago. UNCT MAPS Mission Team 25 April 2017
A Roadmap for SDG Implementation in Trinidad and Tobago UNCT MAPS Mission Team 25 April 2017 A ROADMAP TOWARDS SDG IMPLEMENTATION I. Alignment: The Rapid Integrated Assessment II. From planning to action:
More informationFor the implementation of the WHO multimodal hand hygiene improvement strategy
Template Action Plan For the implementation of the WHO multimodal hand hygiene improvement strategy Introduction The Template Action Plan is proposed to help representatives from health-care facilities
More informationKey Population Engagement in Global Fund
Key Population Engagement in Global Fund Country Dialogue CCMs and the 2017-2019 funding cycle 1 Key Population Engagement in Global Fund Country Dialogue CCMs and the 2017-2019 funding cycle This resource
More informationMinimal Information Model for Patient Safety Incident Reporting and Learning Systems USER GUIDE
Minimal Information Model for Patient Safety Incident Reporting and Learning Systems USER GUIDE Minimal Information Model for Patient Safety Incident Reporting and Learning Systems USER GUIDE WHO/HIS/SDS/2016.22
More informationQuality Framework. for a High Performing Health and Wellness System in Nova Scotia
Quality Framework for a High Performing Health and Wellness System in Nova Scotia Quality Framework for a High Performing Health and Wellness System in Nova Scotia Crown copyright, Province of Nova Scotia,
More information2014 Policy Discussion Paper Submitted June 2014
2014 Policy Discussion Paper Submitted June 2014 As the governments of the United States and Israel prepare for the 2014 Joint Economic Development Group meetings, the U.S. Chamber of Commerce s U.S.-
More informationPharmacy Practice Standards Based on Science, Driven by Evidence
Pharmacy Practice Standards Based on Science, Driven by Evidence Henri Manasse Jr., Ph.D., Sc.D. (Hon.), FIP Chair, FIPEd Steering Committee Professor and Dean Emeritus University of Illinois at Chicago,
More informationWashington County Public Health
Washington County Public Health Strategic Plan 2012-2016 Message from the Division Manager I am pleased to present the Washington County Public Health Division s strategic plan for fiscal years 2012 to
More informationUSAID/Philippines Health Project
USAID/Philippines Health Project 2017-2021 Redacted Concept Paper As of January 24, 2017 A. Introduction This Concept Paper is a key step in the process for designing a sector-wide USAID/Philippines Project
More informationPennsylvania Patient and Provider Network (P3N)
Pennsylvania Patient and Provider Network (P3N) Cross-Boundary Collaboration and Partnerships Commonwealth of Pennsylvania David Grinberg, Deputy Executive Director 717-214-2273 dgrinberg@pa.gov Project
More informationEconomic and Social Council
United Nations Economic and Social Council Distr.: General 10 December 2001 E/CN.3/2002/19 Original: English Statistical Commission Thirty-third session 5-8 March 2002 Item 6 of the provisional agenda*
More informationOverview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Overview of ICH June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Legal notice Legal Notice This presentation is protected by copyright and
More informationFood and Agriculture Organization of the United Nations
Food and Agriculture Organization of the United Nations Support to the EU Programme on Linking Information and Decision-Making to Improve Food Security for Selected Greater Mekong Sub- Regional Countries
More informationA Career in Big Pharma. Beatrice Tilt, GSK
A Career in Big Pharma Beatrice Tilt, GSK Media Disclaimer To confirm that the opinions you hear from me are totally my own and do not reflect the views and opinions of GSK in any way. 2 Academic background
More informationPeople s Republic of China: Strengthening the Role of E-Commerce in Poverty Reduction in Southwestern Mountainous Areas in Chongqing
Technical Assistance Report Project Number: 51022-001 Knowledge and Support Technical Assistance (KSTA) December 2017 People s Republic of China: Strengthening the Role of E-Commerce in Poverty Reduction
More informationTowards a Common Strategic Framework for EU Research and Innovation Funding
Towards a Common Strategic Framework for EU Research and Innovation Funding Replies from the European Physical Society to the consultation on the European Commission Green Paper 18 May 2011 Replies from
More informationThis document is being disclosed to the public in accordance with ADB s Public Communications Policy 2011.
Technical Assistance Report Project Number: 51336-001 Knowledge and Support Technical Assistance (KSTA) February 2018 Capacity Building Support for Asia-Pacific Economic Cooperation Financial Regulators
More informationNorth School of Pharmacy and Medicines Optimisation Strategic Plan
North School of Pharmacy and Medicines Optimisation Strategic Plan 2018-2021 Published 9 February 2018 Professor Christopher Cutts Pharmacy Dean christopher.cutts@hee.nhs.uk HEE North School of Pharmacy
More informationCollege of American Pathologists. Senior Director, Legislation and Political Action Position Profile October 2012
College of American Pathologists Senior Director, Legislation and Political Action Position Profile October 2012 This profile provides information about the College of American Pathologists (CAP) and the
More informationCollaboration of WHO with the Regions and Countries
Collaboration of WHO with the Regions and Countries Dr Cécile Macé Essential Medicines and Health Products Department Technical Briefing Seminar on Pharmaceutical Policies, Nov 2015 1 English TBS Nov 2015
More informationREQUEST FOR PROPOSALS:
CITY AND COUNTY OF SAN FRANCISCO OFFICE OF CIVIC ENGAGEMENT & IMMIGRANT AFFAIRS REQUEST FOR PROPOSALS: LANGUAGE ACCESS COMMUNITY GRANTS I N F O R M A T I O N P A C K E T # 2 0 1 7-01 Date Issued: April
More informationMedicaid Efficiency and Cost-Containment Strategies
Medicaid Efficiency and Cost-Containment Strategies Medicaid provides comprehensive health services to approximately 2 million Ohioans, including low-income children and their parents, as well as frail
More informationThe Health Sector Transformation Plan (HSTP) Federal Democratic Republic of Ethiopia, Ministry of Health
The Health Sector Transformation Plan (HSTP) Federal Democratic Republic of Ethiopia, Ministry of Health Strategic themes of HSTP Key words (HSTP) Quality and equity Universal health coverage Transformation
More informationIHR News The WHO quarterly bulletin on IHR implementation
IHR News The WHO quarterly bulletin on IHR implementation 20 December 2012, No. 20 Issued by the Global Capacities Alert and Response Department World Health Organization (WHO), Geneva and Lyon http://www.who.int/ihr/
More informationPublic health, innovation and intellectual property: global strategy and plan of action
EXECUTIVE BOARD EB126/6 126th Session 3 December 2009 Provisional agenda item 4.3 Public health, innovation and intellectual property: global strategy and plan of action Report by the Secretariat 1. The
More informationWhat is closing space grant-making?
Funders Initiative for Civil Society What is closing space grant-making? An emerging framework from the Funders Initiative for Civil Society What is closing space grant-making? How do we support civil
More informationStandards for Registered Pharmacies
Council meeting 13 September 2012 Public business Standards for Registered Pharmacies Purpose This paper seeks the Council s approval of the standards for registered pharmacies. The Council is asked to
More informationGLOBAL CHRONIC RESPIRATORY DISEASES ALLIANCE AGAINST ACTION PLAN
GLOBAL ALLIANCE AGAINST CHRONIC RESPIRATORY DISEASES ACTION PLAN 28-213 GLOBAL ALLIANCE AGAINST CHRONIC RESPIRATORY DISEASES ACTION PLAN 28-213 WHO Library Cataloguing-in-Publication Data : Action plan
More informationEconomic Burden of Counterfeit Medicine in Africa: Situation Analysis and Proposed Solution
Patient Access Economic Burden of Counterfeit Medicine in Africa: Situation Analysis and Proposed Solution Kasem S Akhras Head, Patient Access MENA ISPOR Annual European Meeting Africa Network Forum October
More informationGuidelines for Accreditation of Medical Schools in Countries of the South-East Asia Region
Guidelines for Accreditation of Medical Schools in Countries of the South-East Asia Region Regional Office for South-East Asia SEA-HSD-318 Distribution: General Guidelines for Accreditation of Medical
More informationNorthern Melbourne Medicare Local COMMISSIONING FRAMEWORK
Northern Melbourne Medicare Local INTRODUCTION The Northern Melbourne Medicare Local serves a population of 679,067 (based on 2012 figures) residing within the municipalities of Banyule, Darebin, Hume*,
More informationRPS in Scotland has had an influential year providing both written and oral evidence at the Scottish Parliament in a wide range of policy areas.
Speech by RPS President Ash Soni at the RPS Annual Conference 2017 3 September 2017 Thank you Paul and let me say how pleased I am as a member that you identified exactly the right areas where I and the
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
EXECUTIVE BOARD EB142/14 Rev.1 142nd session 26 January 2018 Agenda item 3.7 Global strategy and plan of action on public health, innovation and intellectual property Report by the Director-General 1.
More informationWHO supports countries to develop responsive and resilient health systems that are centred on peoples needs and circumstances
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Service delivery Health workforce WHO supports countries to develop responsive and resilient health systems that are centred on peoples needs and circumstances Information
More informationNCL MEDICATION ADHERENCE CAMPAIGN FREQUENTLY ASKED QUESTIONS 2013
NCL MEDICATION ADHERENCE CAMPAIGN FREQUENTLY ASKED QUESTIONS 2013 1. WHAT EXACTLY IS MEDICATION ADHERENCE? Adhering to medication means taking the medication as directed by a health care professional-
More informationQuality Strategy and Improvement Plan
Quality Strategy and Improvement Plan 2015-2018 STRATEGY DOCUMENT DETAILS Status: FINAL Originating Date: October 2015 Date Ratified: Next Review Date: April 2018 Accountable Director: Strategy Authors:
More informationFoundation Pharmacy Framework
Association of Pharmacy Technicians UK Foundation Pharmacy Framework A framework for professional development in foundation across pharmacy APTUK Foundation Pharmacy Framework The Professional Leadership
More informationUSAID s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program ( )
USAID s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program (2011-2016) IR* 1: Pharmaceutical sector governance strengthened 1.1 Good governance principles embodied across all health
More informationComing to a Crossroad: The Future of Long Term Care in Ontario
Coming to a Crossroad: The Future of Long Term Care in Ontario August, 2009 Association of Municipalities of Ontario 200 University Avenue, Suite 801 Toronto, ON M5H 3C6 Canada Tel: 416-971-9856 Fax: 416-971-6191
More informationWHO World Alliance for Patient Safety Conference. Official opening by Hon Charity K Ngilu MP, Minister for Health.
1 17 January 2005 WHO World Alliance for Patient Safety Conference Official opening by Hon Charity K Ngilu MP, Minister for Health 17 January, 2005 Safari Park Hotel, Nairobi From: 9.00 am Sir Liam Donaldson,
More informationA Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership
A Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership 1. Innovation in the life sciences must be a government priority. Since the ability of
More informationRecommendations: 1. Access to information is limiting effective NGO participation
NGO Participation in the Global Fund A Review Paper October 2002 This paper summarises a review undertaken by the International HIV/AIDS Alliance i (the Alliance) in August and September 2002, assessing
More informationAsia Pacific Strategy for Strengthening Health Laboratory Services ( )
WHO Library Cataloguing in Publication Data Asia Pacific strategy for strengthening health laboratory services. 1. Laboratories standards. 2. Laboratory techniques and procedures standards. 3. Quality
More informationPHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA 6 TH TECHNICAL COMMITTEE MEETING NOVEMBER 2015 ADDIS ABABA, ETHIOPIA CONCEPT NOTE
PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA 6 TH TECHNICAL COMMITTEE MEETING 28-29 NOVEMBER 2015 ADDIS ABABA, ETHIOPIA CONCEPT NOTE THEME: PMPA +10: WHERE ARE WE? P a g e 1 1. Background Over the past
More informationMongolia. Situation Analysis. Policy Context Global strategy on women and children/ commitment. National Health Sector Plan and M&E Plan
COUNTRY ACCOUNTABILITY FRAMEWORK: Assessment* Manila, Philippines Accountability Workshop, March 19-20, 2012 Information updated: April 19, 2012 Policy Context Global strategy on women and children/ commitment
More informationIntroduction Patient-Centered Outcomes Research Institute (PCORI)
2 Introduction The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit health research organization authorized by the Patient Protection and Affordable Care Act of 2010. Its
More informationBig data in Healthcare what role for the EU? Learnings and recommendations from the European Health Parliament
Big data in Healthcare what role for the EU? Learnings and recommendations from the European Health Parliament Today the European Union (EU) is faced with several changes that may affect the sustainability
More informationFinal Grant Report Executive Summary
Partnering with the U.S. Coast Guard & Recreational Boating Community to Implement the National Recreational Boating Safety Strategic Plan: NASBLA and the States U.S. Coast Guard Nonprofit Grant No. 3312FAN120206
More informationAPEC Food Safety Cooperation Forum
APEC Food Safety Cooperation Forum APEC Food Safety Cooperation Forum February 2015 Content 1. Background 1 2. FSCF Meetings and Outcomes 7 FSCF 1 st Meeting 7 FSCF 2 nd Meeting 10 FSCF 3 rd Meeting 13
More informationPHILIPPINE MEDICINES POLICY
PHILIPPINE MEDICINES POLICY 2017 2022 C Commitment to Safety, Efficacy, and Quality H Health Literacy and People Empowerment A Accessibility, Availability, and Affordability N Networking and Partnerships
More information09/24/2012. Faculty Disclosure. Session Objectives. Support. IOM Future of Nursing
IOM Future of Nursing Faculty Disclosure Bonnie Osgood MSN, RN-BC, NE-BC President Delaware Nurses Association September 12, 2012 21 st Century Visions of Nursing This presentation is free of sponsorship,
More informationPharmacy Schools Council. Strategic Plan November PhSC. Pharmacy Schools Council
Pharmacy Schools Council Strategic Plan 2017 2021 November 2017 PhSC Pharmacy Schools Council Executive summary The Pharmacy Schools Council is seeking to engage with all stakeholders to support and enhance
More informationFAIRHAVEN VISION Engage. Inspire. Motivate.
FAIRHAVEN VISION Engage. Inspire. Motivate. STRATEGIC PLAN 2011 2014 1 2 TABLE OF CONTENTS Message from the Executive Director 3 Executive Summary 4 Strategic Planning Process Overview 5-6 Mission 7 Vision
More informationProvided below is the background, discussion, and recommendations from the panelists.
Pharmacovigilance is neither a luxury nor a distraction; it is a necessity Conclusions of a High Level Panel on Access and Patient Safety at the Africa Pharmacovigilance Meeting 2012 held at the Intercontinental
More informationBriefing. NHS Next Stage Review: workforce issues
Briefing NHS Next Stage Review: workforce issues Workforce issues, and particularly the importance of engaging and involving staff, are a central theme of the NHS Next Stage Review (NSR). It is the focus
More informationConfronting the Challenges of Rare Disease:
Confronting the Challenges of Rare Disease: SOLUTIONS ACROSS THE ENTIRE PRODUCT LIFE CYCLE The Orphan Drug Act of 1983 brought increased awareness to the need for new treatments for rare disease patients
More information